

D. Goto

8/2/02

#26



RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/413,109

DATE: 08/02/2002

TIME: 13:54:53

Input Set : N:\Crf3\RULE60\09413109.raw

Output Set: N:\CRF3\08022002\I413109.raw

SEQUENCE LISTING

3 (1) GENERAL INFORMATION:  
6 (i) APPLICANT: University of Texas System  
8 (ii) TITLE OF INVENTION: RECOMBINANT P53 ADENOVIRUS METHODS  
9 AND COMPOSITIONS  
11 (iii) NUMBER OF SEQUENCES: 4  
13 (iv) CORRESPONDENCE ADDRESS:  
15 (A) ADDRESSEE: Arnold, White & Durkee  
16 (B) STREET: P.O. Box 4433  
17 (C) CITY: Houston  
18 (D) STATE: Texas  
19 (E) COUNTRY: USA  
20 (F) ZIP: 77210  
22 (v) COMPUTER READABLE FORM:  
24 (A) MEDIUM TYPE: Floppy Disk  
25 (B) COMPUTER: IBM PC Compatible  
26 (C) OPERATING SYSTEM: PC-DOS/MS-DOS  
27 (D) SOFTWARE: ASCII-DOS  
29 (vi) CURRENT APPLICATION DATA:  
C--> 31 (A) APPLICATION NUMBER: US/09/413,109  
C--> 32 (B) FILING DATE: 06-Oct-1999  
33 (C) CLASSIFICATION:  
36 (vii) PRIOR APPLICATION DATA:  
38 (A) APPLICATION NUMBER: 08/145,826  
39 (B) FILING DATE:  
C--> 48 (viii) ATTORNEY/AGENT INFORMATION:  
44 (A) NAME: Barbara S. Kitchell  
45 (B) REGISTRATION NUMBER: 33,528  
46 (C) REFERENCE/DOCKET NUMBER: UTSC:350  
C--> 0 (ix) TELECOMMUNICATION INFORMATION:  
50 (A) TELEPHONE: (512) 320-7200  
51 (B) TELEFAX: (512) 474-7577  
53 (2) INFORMATION FOR SEQ ID NO: 1:  
55 (i) SEQUENCE CHARACTERISTICS:  
57 (A) LENGTH: 19  
58 (B) TYPE: Nucleic acid  
59 (C) STRANDEDNESS: Single  
60 (D) TOPOLOGY: Linear  
W--> 62 (ii) MOLECULE TYPE:  
C--> 64 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:  
66 GGCCACCCC CTTGGCTTC  
68 (2) INFORMATION FOR SEQ ID NO: 2:  
70 (i) SEQUENCE CHARACTERISTICS:

ENTERED

19

RAW SEQUENCE LISTING  
 PATENT APPLICATION: US/09/413,109

DATE: 08/02/2002  
 TIME: 13:54:53

Input Set : N:\Crf3\RULE60\09413109.raw  
 Output Set: N:\CRF3\08022002\I413109.raw

```

72      (A) LENGTH: 20
73      (B) TYPE: Nucleic acid
74      (C) STRANDEDNESS: Single
75      (D) TOPOLOGY: Linear
W--> 77      (ii) MOLECULE TYPE:
C--> 79      (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:
81      TTGTAACCAT TATAAGCTGC                                20
83 (2) INFORMATION FOR SEQ ID NO: 3:
85      (i) SEQUENCE CHARACTERISTICS:
87      (A) LENGTH: 20
88      (B) TYPE: Nucleic acid
89      (C) STRANDEDNESS: Single
90      (D) TOPOLOGY: Linear
W--> 92      (ii) MOLECULE TYPE:
C--> 94      (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:
96      TCGTTTCTCA GCAGCTGTTG                                20
98 (2) INFORMATION FOR SEQ ID NO: 4:
100     (i) SEQUENCE CHARACTERISTICS:
102     (A) LENGTH: 20
103     (B) TYPE: Nucleic acid
104     (C) STRANDEDNESS: Single
105     (D) TOPOLOGY: Linear
W--> 107     (ii) MOLECULE TYPE:
C--> 109     (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:
111     CATCTGAACT CAAAGCGTGG                                20

```

RAW SEQUENCE LISTING ERROR SUMMARY  
PATENT APPLICATION: US/09/413,109

DATE: 08/02/2002  
TIME: 13:54:54

Input Set : N:\Crf3\RULE60\09413109.raw  
Output Set: N:\CRF3\08022002\I413109.raw

Invalid Line Length:

The rules require that a line not exceed 72 characters in length. This includes spaces.

Seq#:1; Line(s) 68  
Seq#:2; Line(s) 83  
Seq#:3; Line(s) 98

## VERIFICATION SUMMARY

PATENT APPLICATION: US/09/413,109

DATE: 08/02/2002

TIME: 13:54:54

Input Set : N:\Crif3\RULE60\09413109.raw

Output Set: N:\CRF3\08022002\I413109.raw

L:31 M:220 C: Keyword misspelled or invalid format, [(A) APPLICATION NUMBER:]  
L:32 M:220 C: Keyword misspelled or invalid format, [(B) FILING DATE:]  
L:42 M:220 C: Keyword misspelled or invalid format, [(viii) ATTORNEY/AGENT INFORMATION:]  
L:48 M:220 C: Keyword misspelled or invalid format, [(viii) ATTORNEY/AGENT INFORMATION:]  
L:0 M:247 C: Inserted Optional Header Field, [(ix) TELECOMMUNICATION INFORMATION:]  
L:64 M:220 C: Keyword misspelled or invalid format, [(xi) SEQUENCE DESCRIPTION: SEQ ID NO:]  
L:62 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo=1  
L:79 M:220 C: Keyword misspelled or invalid format, [(xi) SEQUENCE DESCRIPTION: SEQ ID NO:]  
L:77 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo=2  
L:94 M:220 C: Keyword misspelled or invalid format, [(xi) SEQUENCE DESCRIPTION: SEQ ID NO:]  
L:92 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo=3  
L:109 M:220 C: Keyword misspelled or invalid format, [(xi) SEQUENCE DESCRIPTION: SEQ ID NO:]  
L:107 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo=4

**T. D. INFORMAL MEMO: DO NOT MAIL THIS MEMO TO APPLICANT**DATE: 7-29-02TO: EXAMINER D. HugoAPPL. S.N.: 09/4/3109FROM: E. Williams  
PARALEGAL SPECIALISTART UNIT: 1636SUBJECT: Decision on Terminal Disclaimer (T.D.) filed: 7-9-02

INSTRUCTIONS: I have reviewed the submitted T.D. with the results as set forth below. If you agree, please use the appropriate form paragraphs identified by this informal memo in your next Office action to notify applicant of the T.D. If you disagree or have any questions, please see me or the Special Program Examiner. THIS IS AN INFORMAL, INTERNAL MEMO ONLY. IT MUST NOT BE (1) MAILED TO APPLICANT OR (2) PLACED OF RECORD IN THE APPLICATION FILE. When your action is complete, please initial, date and return this memo to me. THANK YOU.

- ☒ The T.D. is PROPER and has been recorded (see ¶ 14.23).
- ☐ The T.D. is NOT PROPER and has not been accepted for the reason(s) checked below (see ¶ 14.24):
- ☐ The recording fee of \$ \_\_\_\_\_ has not been submitted nor is there any authorization in the application file for the use of a deposit account (see ¶ 14.26.07).
  - ☐ The T.D. does not satisfy Rule 321 in that the person who has signed the T.D. has not stated the extent of his/her interest (and/or the extent of the interest of the business entity represented by the signature) in the application/patent (see ¶¶ 14.26 & 14.26.01).
  - ☐ The T.D. lacks the enforceable only during common ownership clause - needed to overcome a double patenting rejection, Rule 321(b) (see ¶ 14.27.01).
  - ☐ The T.D. is directed to a particular claim(s), which is not acceptable since "the disclaimer must be a terminal portion of the term of the entire patent to be granted." (MPEP 1490) (see ¶¶ 14.26 & 14.26.02).
  - ☐ The person who signed the T.D.:
    - ☐ is not an attorney "of record" (see ¶¶ 14.29 and 14.29.01).
    - ☐ has failed to state his/her capacity to sign for the business entity (see ¶ 14.28),
    - ☐ is not recognized as an officer of the assignee (see ¶¶ 14.29 & possibly 14.29.02).
  - ☐ No documentary evidence of a chain of title from the original inventor(s) to assignee has been submitted, nor is the reel and frame number specified as to where such evidence is recorded in the Office (see 37 CFR 3.73(b) and 1140 O.G. 72). NOTE: This documentary evidence or the specifying of the reel and frame number may be found in the T.D. or in a separate paper of record in the application (see ¶ 14.30).
  - ☐ The T.D. is not signed (see ¶¶ 14.26 & 14.26.03).
  - ☐ The serial number of the application (or the number of the patent) which forms the basis for the double patenting rejection is missing or incorrect (see ¶ 14.32).
  - ☐ The serial number of this application (or the number of the patent in reexam or reissue cases being disclaimed is missing or incorrect (see ¶¶ 14.26, 14.26.04 or 14.26.05).
  - ☐ The period disclaimed is incorrect or not specified (see ¶¶ 14.26, 14.27.02 or 14.27.03).
  - ☐ Other:
  - ☐ Suggestion to request refund (see ¶ 14.36). NOTE: If already authorized, credit refund to deposit account and do not check this item.

I have appropriately notified applicant(s) of the status of the Terminal Disclaimer filed in this case.

Ex. Initials: \_\_\_\_\_ Date: \_\_\_\_\_

RETURN THIS MEMO TO CPK2-2D25.

(Rev. 5/98)